Online inquiry

IVTScrip™ mRNA-Human ANKRD10, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK14897MR)

This product GTTS-WK14897MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the ANKRD10 protein. This product can be used in Exhausted CD8+ T cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001286721.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 55608
UniProt ID Q9NXR5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ANKRD10, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WK14897MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK24687MR IVTScrip™ mRNA-Human ARHGAP21, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARHGAP21
GTTS-WK5235MR IVTScrip™ mRNA-Human CD9, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD9
GTTS-WK10401MR IVTScrip™ mRNA-Human ADAMTS17, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADAMTS17
GTTS-WK19426MR IVTScrip™ mRNA-Human ANKRD44, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANKRD44
GTTS-WK20536MR IVTScrip™ mRNA-Human alpha-Sarcoglycan, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA alpha-Sarcoglycan
GTTS-WK10761MR IVTScrip™ mRNA-Human ADORA2B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADORA2B
GTTS-WK7579MR IVTScrip™ mRNA-Human ABLIM2, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABLIM2
GTTS-WK15503MR IVTScrip™ mRNA-Human ANKRD17, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANKRD17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW